ArticleOncotarget2015

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.

Giovanni Lo Re et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.